Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
10,370
Employees10,370
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
10,370
Employees10,370

ILMN Key Statistics

Market cap
18.30B
Market cap18.30B
Price-Earnings ratio
24.52
Price-Earnings ratio24.52
Dividend yield
Dividend yield
Average volume
2.40M
Average volume2.40M
High today
$128.16
High today$128.16
Low today
$117.67
Low today$117.67
Open price
$125.17
Open price$125.17
Volume
4.45M
Volume4.45M
52 Week high
$155.53
52 Week high$155.53
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $119.80, with a market capitalization of 18.3B. The stock trades at a price-to-earnings (P/E) ratio of 24.52.

On 2026-02-06, Illumina(ILMN) stock moved within a range of $117.67 to $128.16. With shares now at $119.80, the stock is trading +1.8% above its intraday low and -6.5% below the session's peak.

Trading activity shows a volume of 4.45M, compared to an average daily volume of 2.4M.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

ILMN News

TipRanks 20m
Illumina Earnings Call Highlights Clinical Growth Momentum

Illumina ((ILMN)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and po...

TipRanks 10h
Illumina price target raised to $137 from $132 at Baird

Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Illumina (ILMN) to $137 from $132 and keeps a Neutral rating on the shares. The firm up...

TipRanks 11h
Illumina price target lowered to $150 from $155 at Evercore ISI

Evercore ISI lowered the firm’s price target on Illumina (ILMN) to $150 from $155 and keeps an Outperform rating on the shares. Execution reaffirms the turnarou...

Analyst ratings

43%

of 23 ratings
Buy
39.1%
Hold
43.5%
Sell
17.4%

More ILMN News

Nasdaq 1d
Illumina Q4 2025 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Illumina Q4 2025 Earnings Call Transcript
Nasdaq 1d
Illumina Inc. Q4 Profit Advances

(RTTNews) - Illumina Inc. (ILMN) released earnings for its fourth quarter that Increases, from the same period last year The company's bottom line came in at $...

Illumina Inc. Q4 Profit Advances
TipRanks 1d
Illumina reports Q4 adjusted EPS $1.35, consensus $1.23

Reports Q4 revenue $1.16B, consensus $1.11B. “The Illumina (ILMN) team delivered a strong finish to 2025, marking a return to growth through disciplined executi...

Simply Wall St 2d
Illumina Wildlife Genomics Deal Highlights New Conservation And Valuation Story

Illumina (NasdaqGS:ILMN) has partnered with the San Diego Zoo Wildlife Alliance's Frozen Zoo to sequence thousands of endangered species samples. The collabora...

Illumina Wildlife Genomics Deal Highlights New Conservation And Valuation Story
TipRanks 3d
Illumina partners with San Diego Zoo Wildlife Alliance for genetics conservation

Illumina (ILMN) announced a sequencing agreement with the San Diego Zoo Wildlife Alliance’s Frozen Zoo. The 50-year-old biobank is the world’s most comprehensiv...

Simply Wall St 4d
Does CMS Backing of TruSight Oncology Recast Illumina’s Clinical Genomics Potential?

Illumina, Inc. recently secured CMS reimbursement for its FDA-approved TruSight Oncology Comprehensive in vitro diagnostic test, effective January 1, 2026, at a...

Does CMS Backing of TruSight Oncology Recast Illumina’s Clinical Genomics Potential?
Simply Wall St 6d
A Look At Illumina Valuation As Recent Returns Contrast With Longer Term Declines

Advertisement Recent performance context for Illumina stock Illumina (ILMN) has drawn investor attention after a 1-month return of 7.8% and a past 3-month ret...

A Look At Illumina Valuation As Recent Returns Contrast With Longer Term Declines

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.